D

    Dogwood Therapeutics, Inc. (DWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.58
    -0.07 (-2.64%)

    Market Cap: $87.70M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    -564.32%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.16 - $-0.15
    2 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.21-35.5%
    60d ago$-0.14+7.5%
    30d ago$-0.14+7.5%
    7d ago$-0.14+7.5%
    Current$-0.15
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.38
    Range$-0.46 - $-0.31
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.38---
    Sep 26EST
    		-$-0.15---
    Jun 26
    Reported Aug 12
    		$-0.34$-0.13-161.54%Miss+82.9%
    Mar 26
    Reported May 14
    		$-0.15$-0.20+25.00%Beat+98.2%
    Dec 25
    Reported Mar 18
    		$-0.26N/A+69.77%Beat+95.9%
    Sep 25
    Reported Nov 6
    		$-8.20$-1.58-418.99%Miss-300.0%
    Jun 25
    Reported Aug 13
    		$-1.99$-1.90-4.74%Miss-59.2%
    Mar 25
    Reported May 8
    		$-8.45$-0.76-1011.84%Miss-382.9%
    Dec 24
    Reported Feb 26
    		$-6.29$-0.06-10993.47%Miss-10383.3%
    Sep 24
    Reported Nov 7
    		$-2.05$-1.18-73.73%Miss-36.7%
    Jun 24
    Reported Aug 8
    		$-1.25$-1.58+20.89%Beat+37.5%
    Mar 24
    Reported May 9
    		$-1.75$-1.00-75.00%Miss-2087.5%
    Dec 23
    Reported Feb 29
    		$-0.06$-0.06+0.00%Beat+97.8%
    Sep 23
    Reported Nov 13
    		$-1.50$-2.25+33.33%Beat+78.6%
    Jun 23
    Reported Aug 10
    		$-2.00$-1.25-60.00%Miss+81.8%
    Mar 23
    Reported May 11
    		$-0.08$-0.16+50.00%Beat+99.3%
    Dec 22
    Reported Mar 31
    		$-2.75$-3.75+26.67%Beat-409.3%
    Sep 22
    Reported Nov 14
    		$-7.00$-11.50+39.13%Beat+42.9%
    Jun 22
    Reported Aug 11
    		$-11.00$-12.25+10.20%Beat+13.7%
    Mar 22
    Reported May 12
    		$-12.00$-13.75+12.73%Beat-29.7%
    Dec 21
    Reported Mar 31
    		$-0.54$-0.54+0.00%Beat+56.8%
    Sep 21
    Reported Nov 11
    		$-12.25$-17.25+28.99%Beat-3400.0%
    Jun 21
    Reported Aug 12
    		$-12.75$-13.75+7.27%Beat-15837.5%
    Mar 21
    Reported May 13
    		$-9.25N/A+60.22%Beat-
    Dec 20
    Reported Mar 31
    		$-1.25N/AN/ABeat-
    Sep 20
    Reported Dec 18
    		$-0.35$0.00N/AMiss-
    Jun 20
    Reported Aug 28
    		$-0.08$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.29EV/EBITDA0.22x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-47.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.89xQuick Ratio3.89x
    Trading Statistics
    Beta1.76Avg Volume70.66K
    52-Week High$9.5052-Week Low$1.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.47
    SMA 20$2.18
    SMA 50$1.77
    SMA 200$2.78
    EMA 10$2.44
    EMA 20$2.24
    EMA 50$1.95
    EMA 200$2.63

    MACD

    Line: 0.25Signal: 0.22Hist: 0.03

    ADX

    ADX: 53.8+DI: 31.3-DI: 10.6

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down8.0
    PSAR$2.78

    Bollinger Bands

    Upper Band$2.85
    Lower Band$1.52
    %B Position6119%(Upper)
    Band Width0.80

    RSI (14-Day)

    Neutral
    66.4

    Momentum Oscillators

    Stoch %K72.7
    Stoch %D75.5
    Williams %R-22.7
    ROC (10d)25.2%
    Momentum0.52
    CCI (20d)99.4
    MFI (14d)89.2

    Volatility Measures

    ATR (14d)$0.21(8.1%)
    StdDev (20d)0.33
    Hist Vol89.8%(High)

    Volume Flow

    VWAP$2.62
    OBV123.7M
    AD Line-33.6M
    CMF (20d)0.202

    Volume Metrics

    Avg Vol (20d)70.0K
    Vol Ratio0.9x
    VWMA (20d)$2.32

    Pivot Points

    R3$3.13
    R2$2.92
    R1$2.78
    Pivot Point$2.57
    S1$2.43
    S2$2.22
    S3$2.08

    Advanced Oscillators

    TSI45.53
    Ultimate Osc50.7
    KST543.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$12,177$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0$-12,177$0$0$0N/A$0
    Operating Expenses$14.06M$5.08M$3.81M$15.81M$3.92M$4.43M$7.54M$2.30M$1.07M$1.31M$1.14M$1.27M
    R&D$3.25M$2.67M$2.34M$14.52M$2.57M$2.44M$2.32M$535,162$336,084$343,717$298,321$374,200
    SG&A$1.63M$2.41M$1.47M$1.29M$1.35M$1.99M$5.23M$1.77M$733,740$970,384$839,805$900,089
    Operating Income$-14,063,525$-5,076,366$-3,806,279$-15,809,125$-3,923,115$-4,429,926$-7,542,151$-2,301,172$-1,069,824$-1,314,101$-1,138,126$-1,274,289
    Interest Income$66,349$77,350$52,067$80,582$111,379$-147,090$-155,437$20,488$19,991$22,766$0$39,215
    Interest Expense$0$0$0$0$0$6.13M$186,224$0$0$0$0$0
    Income Before Tax$-14,010,303$-4,985,421$-3,748,608$-15,746,052$-3,807,204$-10,734,410$-7,728,375$-2,280,684$-1,049,833$-1,291,335$-1,103,173$-1,235,074
    Income Tax Expense$-2,480,694$1,193$31,841$-1,436$149$190,542$-503$0$0$0$0$0
    Net Income$-11,529,609$-4,986,614$-3,780,449$-15,744,616$-3,807,353$-10,924,952$-7,727,872$-2,280,684$-1,049,833$-1,291,335$-1,103,173$-1,235,074
    EBITDA$-14,076,652$-5,082,226$-3,797,944$-15,858,849$-3,901,327$-4,383,805$-7,502,329$-2,301,172$-1,069,824$-1,314,101$-1,138,126$-1,274,289
    EBIT$-14,076,652$-5,082,226$-3,797,944$-15,826,634$-3,918,583$-4,453,200$-7,572,938$-2,301,172$-1,069,824$-1,314,101$-1,138,126$-1,274,289
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DWTX

    News

    VIRI stock trades cautiously as Virios Therapeutics pursues strategic options after reverse stock sp

    Virios Therapeutics Inc. (VIRI) is cautiously trading after a reverse stock split and continues to explore strategic options amidst financial constraints in 2024. The biotechnology company, focused on developing treatments for chronic diseases triggered by herpes viruses like fibromyalgia, has reported a net loss and modest cash reserves. Its enterprise value is tied to future trial results and licensing opportunities rather than current earnings.

    Ad-hoc-news.de•7/22/26•
    Neutral

    Virios Therapeutics weighs strategic options as development focus remains on fibromyalgia

    Virios Therapeutics is evaluating strategic options while focusing its clinical development on fibromyalgia and related conditions. The company, a clinical-stage biotechnology firm, specializes in antiviral-based therapies for chronic pain and fatigue, particularly fibromyalgia, and emphasizes well-structured clinical trials to advance its pipeline. Its ability to secure funding and establish partnerships will be crucial for the long-term success and commercialization of its therapies.

    AD HOC NEWS•7/8/26•
    Neutral

    Virios Therapeutics Stock (US92765A1034): Quarterly earnings keep micro-cap biotech in focus

    Virios Therapeutics (VIRI) is a micro-cap biotech focused on treating fibromyalgia, with its stock performance heavily influenced by quarterly earnings and cash burn rates. As the company has no approved products, investor focus remains on R&D expenses, administrative costs, and the cash runway to fund clinical trials for its lead candidate IMC-1. The company's future value depends on generating positive clinical data to support a regulatory submission, making operational updates and clinical milestones crucial for investor sentiment.

    AD HOC NEWS•6/16/26•
    Neutral

    Frequently Asked Questions About DWTX

    Does DWTX pay dividends?
    Dogwood Therapeutics, Inc. (DWTX) does not currently pay a regular dividend.
    What is DWTX's market cap?
    Dogwood Therapeutics, Inc. (DWTX) has a market capitalization of $87.70M with a current stock price of $2.58.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In